Steps Toward Building Grassroots Support

December 6, 2017 Since the FDA hearing and the FTC workshop in 2015, the homeopathic industry has received more attention than usual from regulators. While AAHP continually meets with congressional…

Read More

Recall Preparedness

By Mark Land, AAHP president November 20, 2017 Risks associated with the therapeutic use of healthcare products are real. Manufacturers and the U.S. Food and Drug Administration (FDA) balance these…

Read More

The Long-Term Vision for AAHP

The long term

By Eric Foxman, AAHP secretary October 1, 2017 During the course of the summer, AAHP president Mark Land lead the various association committees in an intense introspective series of meetings…

Read More

Market Research Roundup

Market research roundup

By Eric Foxman, AAHP secretary October 1, 2017 The last weeks have seen a number of market research studies published that provide background, analysis, and forecasts for homeopathic market development…

Read More

Belladonna: A Clinical Snapshot

By Todd Hoover, MD September 1, 2017 The original proving of belladonna was conducted by Dr. Samuel Hahnemann, who found it to become a commonly used medicine. Dr. Hahnemann described…

Read More

How is Homeopathic Belladonna Made?

By Mark Land, AAHP president September 1, 2017 Belladonna, more commonly known as deadly nightshade, Atropa belladonna, devil’s cherries, devil’s herb, divale, dwale, dwayberry, great morel, naughty man’s cherries, and poison…

Read More

What’s New at FDA?

By Mark Land, AAHP president September 1, 2017 I took a course several years ago titled Regulatory Intelligence. The first thing the professor said was, “This course is not designed…

Read More